
Synthetic Data for Rare Subgroups – A Decision-Grade Tool to Inform Drug Development
In drug development, access to diverse and representative patient data is often a limiting factor, especially when studying rare subgroups. This is where synthetic data can offer powerful, practical value. At InSilicoTrials, we use synthetic data not as a replacement … Read More

Synthetic Data – Are We All Talking About the Same Thing?
Synthetic Data’ – Are We All Talking About the Same Thing? In the rapidly evolving world of healthcare and drug development, data is the driving force behind innovation. Yet, the lack of cross-institute shared access frameworks and the need to … Read More

InSilicoTrials Highlighted in HSBC Venture Healthcare Report for 1H 2024
The HSBC Healthcare Annual Report for the first half of 2024 provides an extensive analysis of the healthcare sector, focusing on trends in venture capital investments, biopharma, medical devices, and health tech. This report, authored by HSBC Innovation Banking, serves … Read More

FDA DRAFT GUIDANCE: Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies Guidance for Industry
In recent years, the US Congress and the US Food and Drug Administration (FDA) have emphasized the importance of including underrepresented populations in clinical trials. This push for diversity is not just a regulatory requirement but a critical step towards … Read More

Charting New Horizons for Clinical Trials: InSilicoTrials at DIA 2024
InSilicoTrials recently participated in the DIA 2024 Global Annual Meeting, (16-20 June, San Diego), sharing valuable insights on the use of in silico trials, digital twins, and AI-powered predictive intelligence in drug development and patient care. This event provided a … Read More

In Silico Technologies: A Strategic Imperative for Accelerating Breakthroughs and Market Leadership for FDA-Regulated Products
InSilicoTrials recently collaborated with a team of experts led by Tina M. Morrison on a significant initiative supported by the FDA and the U.S. Department of Health and Human Services. The project, titled “A Strategic Imperative for Accelerating Breakthroughs and … Read More

Living with Amyotrophic Lateral Sclerosis
The BRAINTEASER Community of Practice Second webinar Advances in digital technology are helping us to predict the onset of a disease, how it will progress, or which is the best treatment option for a particular person. In other words, technology … Read More

Axoltis Pharma receives authorization to launch SEALS – phase II clinical trial for ALS patients with drug candidate NX210c
InSilicoTrials partners with Axoltis Pharma to leverage advanced modeling technology, generating predictive analyses of disease progression in virtual subjects based on the baseline characteristics of actual enrolled patients. This collaboration will enhance the development of Axoltis’s NX210c by accelerating the … Read More

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference
InSilicoTrials collaborates with Telomir Pharmaceuticals, applying cutting-edge AI and simulation technologies to optimize the development of Telomir-1, a promising agent in the battle against age-related conditions, by improving its safety profile and reducing development costs. BALTIMORE, March 07, 2024 (GLOBE … Read More